Share this article on:

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

Landman, Rolanda; Damond, Florenceb,c; Gerbe, Juliettea; Brun-Vezinet, Francoiseb,c,d; Yeni, Patricka,d; Matheron, Sophiea,d

doi: 10.1097/QAD.0b013e328321305a
Research Letters

Among the 3700 HIV-infected patients followed in our institution, 17 with regular clinical, immunological and virological follow-up and identified as being dually seropositive for HIV-1 and HIV-2 were included in this study. Antiretroviral therapy seemed to be as effective, in terms of virological and immunological response, as in patients infected by HIV-1 alone. Nevertheless, the observed selection of HIV-2 protease resistance mutations in two cases underlines the importance of selecting drugs that are active on both viruses.

aAP-HP, Groupe hospitalier Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, France

bAP-HP, Groupe hospitalier Bichat-Claude Bernard, Laboratoire de Virologie, France

cINSERM U552, France

dUniversity Denis Diderot-Paris 7, Paris, France.

Received 24 October, 2008

Accepted 3 November, 2008

HIV-1 and HIV-2 both circulate in West Africa, where 0.3–1.0% of HIV-infected patients are estimated to be infected by both viruses [1–5]. Theoretically, HIV-1/HIV-2 dual infection should be defined by the presence of both HIV-1 and HIV-2 DNA or RNA by specific PCR, but as the rate of proviral DNA and plasma RNA HIV-2 detection in it is low [6–9], the diagnosis of such dual infections is complicated. Serology on the basis of specific synthetic peptides has provided useful informations for diagnosing dual seropositivity. In France, mandatory anonymous HIV case reporting was implemented in 2003 and includes routine virological monitoring and serological identification of the HIV type and group. Serological identification of the HIV type and group (HIV-1 groups M and O and HIV-2) is based on subtype serotyping enzyme-linked immunosorbant assay and is applied to all initial sera from newly diagnosed patients [10]. Serological diagnosis of dual infection was based on similar high levels of antibody binding to both the immunodominant epitope of gp41 and the V3 region of both HIV-1 and HIV-2 [11].

Between January 2003 and June 2006, 10 184 new diagnoses of HIV infection with virological monitoring were reported. Of these, 186 involved patients infected by HIV-2, of whom 22 (0.2%; 95% confidence interval = 0.1–0.3) were probably dually seropositive [12].

Among the 3700 HIV-infected patients managed in our institution (Bichat Claude-Bernard Hospital, Paris), 36 have been identified as being dually seropositive for HIV-1 and HIV-2 by specific env (V3 and gp36) peptide serology and confirmed by western blots HIV-1 and HIV-2 since 1994. Among these 36 patients, 17 (10 women) with a regular clinical, immunological and virological follow-up of at least 1 year were included in this retrospective observational study. At diagnosis of the dual seropositivity, the patient's mean ± SD age was 38.1 ± 9.4 years, and nine patients were at Centers for Disease Control and Prevention stage C. The patients mostly originated from West Africa (Ivory Coast, n = 7; Ghana, n = 5; Benin, n = 2; Senegal, Mali and Cameroon, n = 1 each). Six out of the 17 patients had never received antiretroviral therapy (ART), and their 3.6 years of follow-up showed stable CD4 cell count and HIV-1 viral load. In all these patients, the HIV-2 plasma viral load remained undetectable.

Eleven patients received 1–7 different antiretroviral regimens. At the time of first line regimen, their median CD4 cell count was 130 cells/μl (16–290), the median HIV-1 viral load was 4.6 log copies/ml (2.8–5.8) and HIV-2 viral load was detectable in two patients (4.47 and 4.74 log copies/ml). After a median of follow-up of 2.6 years (0.3–7.6), the median CD4 cell count was 338 cells/μl (102–654), and plasma HIV-1 and HIV-2 RNA were undetectable in 10/11 cases. No clinical events were observed during follow-up. The ongoing treatment included lopinavir/ritonavir in nine cases (and two or three nucleoside reverse transcriptase inhibitors, n = 8 and saquinavir, n = 1); atazanavir/ritonavirtenofovir/emtricitabine, n = 1 and darunavir/ritonavir/tenofovir/raltegravir, n = 1. Detectable HIV-2 plasma RNA was observed in two out of the 11 patients during their follow-up. The first one had received five antiretroviral drug combinations between 1996 and 2007. HIV-1 plasma viral load became undetectable on zidovudine/abacavir/lamivudine, but HIV-2 plasma viral load never reached undetectability (2.24–4.78 log copies/ml) (Fig. 1). On the basis of reverse transcriptase and protease gene sequencing, which showed the presence of Q151M+M184V mutations in the reverse transcriptase gene and I54M+I82F in the protease gene, a tenofovir/darunavir/ritonavir/raltegravir combination was prescribed. HIV-2 plasma viral load became undetectable after 1 month and remained below 100 copies/ml for 6 months. The CD4 cell count rose from 102 to 314 cells/μl. The second patient had received didanosine/3TC/atazanavir/ritonavir, then didanosine/3TC/lopinavir/ritonavir combinations. Although HIV-1 viral load became undetectable, HIV-2 plasma viral load ranged from 2.63–4.59 log copies/ml. The HIV-2 reverse transcriptase gene could not be amplified in this patient. Protease gene sequencing showed the presence of the V47A mutation. The CD4 cell count remained stable in the range 315–386 cells/μl.

Fig. 1

Fig. 1

This is the first report on the response to ART in HIV-1 and HIV-2 dually seropositive patients. Treatment seemed to be as effective, in terms of virological and immunological response, as in patients infected by HIV-1 alone [13,14]. Nevertheless, the observed selection of HIV-2 protease inhibitor resistance mutations in the two cases with persistent HIV-2 viral load detectability underlines the importance of selecting drugs that are active on both viruses. These two patients had received atazanavir/ritonavir and did not respond to the subsequent lopinavir/ritonavir-based regimen. This is in keeping with French guidelines, which mention reduced HIV-2 sensitivity to several protease inhibitors, including atazanavir/ritonavir, fosamprenavir/ritonavir and tipranavir/ritonavir [15,16]. We observed the same good virological response to raltegravir combined with an active protease inhibitor (e.g. darunavir) as previously reported in HIV-2-monoinfected patients [17,18]. Immunological and virological follow-up of both HIV-1 and HIV-2 in dually seropositive patients is recommended. The efficacy of drugs on both viruses has to be taken into account for the choice of ART, and new regimens including an integrase inhibitor should be evaluated both in the northern countries and West Africa.

Back to Top | Article Outline


Roland Landman, Florence Damond and Sophie Matheron were responsible for the conception and design; Roland Landman, Florence Damond and Juliette Gerbe were responsible for the provision of study materials or patients; Roland Landman, Florence Damond, Sophie Matheron and Juliette Gerbe provided the statistical expertise and performed the analysis; Drafting of the article was carried out by Roland Landman, Florence Damond and Sophie Matheron; Interpretation of the data, critical revision of the article for important intellectual content, and final approval of the article was carried out by Roland Landman, Florence Damond, S. Matheron, Juliette Gerbe, Francoise Brun-Vezinet and Patrick Yeni.

Back to Top | Article Outline


1. Holmgren B, da Silva Z, Larsen O, Vastrup P, Andersson S, Aaby P. Dual infections with HIV-1, HIV-2 and HTLV-I are more common in older women than in men in Guinea-Bissau. AIDS 2003; 17:241–253.
2. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195–1202.
3. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Coll-Seck AM, Curlin ME, et al. Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. AIDS Res Hum Retroviruses 2003; 19:575–584.
4. Rayfield M, De Cock K, Heyward W, Goldstein L, Krebs J, Kwok S, et al. Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis 1988; 158:1170–1176.
5. Sagoe K, Mingle J, Affram R, Britton S, Dzokoto A, Sonnerborg A. Virological characterization of dual HIV-1/HIV-2 seropositivity and infections in Southern Ghana. Ghana Med J 2008; 42:16–21.
6. Matheron S, Pueyo S, Damond F, Simon F, Campa P, Salamon R, et al. Factors associated with clinical progression in HIV-2 infected patients: the French ANRS cohort. AIDS 2003; 17:2593–2601.
7. Sarr AD, Hamel DJ, Thior I, Kokkotou E, Marlink RG, Coll-Seck EM, et al. HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. AIDS 1998; 12:131–137.
8. Grankvist O, Bredberg-Raden U, Gustafsson A, Albert J, Albino P, Andreasson PA, et al. Improved detection of HIV-2 DNA in clinical samples using a nested primer-based polymerase chain reaction. J Acquir Immune Defic Syndr 1992; 5:286–293.
9. Damond F, Loussert-Ajaka I, Apetrei C, Descamps D, Souquiere S, Lepretre A, et al. Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA. J Clin Microbiol 1998; 36:809–811.
10. Barin F, Lahbabi Y, Buzelay L, Lejeune B, Baillou-Beaufils A, Denis F, et al. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses 1996; 12:1279–1289.
11. Baillou A, Janvier B, Leonard G, Denis F, Goudeau A, Barin F. Fine serotyping of human immunodeficiency virus serotype 1 (HIV-1) and HIV-2 infections by using synthetic oligopeptides representing an immunodominant domain of HIV-1 and HIV-2/simian immunodeficiency virus. J Clin Microbiol 1991; 29:1387–1391.
12. Barin F, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003–2006. AIDS 2007; 21:2351–2353.
13. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141–1150.
14. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451–458.
15. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Campa P, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545–1548.
16. Yeni P. French guidelines for the treatment of HIV-infected adults with antiretroviral therapy. Flammarion 2008:226–238.
17. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091–1092.
18. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665–666.
© 2009 Lippincott Williams & Wilkins, Inc.